Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated with GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 40, Issue 2, 2017, Pages 207-213

  Spitler, Lynn E ^a   Cao, Huynh ^a   Piironen, Timo ^d   Whiteside, Theresa L ^c   Weber, Robert W ^a   Cruickshank, Scott ^b  

^a ST MARY S MEDICAL CENTER   (United States)

^b Cruickshank and Associates   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Syrinx Bioanalytics Oy   (Finland)

Author keywords

adjuvant therapy; clinical trial; GM CSF; melanoma; neutralizing antibodies

Indexed keywords

ANTIBODY; BINDING ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; NEOPTERIN; NEUTRALIZING ANTIBODY; SARGRAMOSTIM; UNCLASSIFIED DRUG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BIOLOGICAL ACTIVITY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURGERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EOSINOPHIL COUNT; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; ADJUVANT CHEMOTHERAPY; AGED; BIOSYNTHESIS; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; BIOLOGICAL PHENOMENA; CHEMOTHERAPY, ADJUVANT; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; MALE; MELANOMA; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 84916226714     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0000000000000124     Document Type: Article

References (37)

1. Melanoma of the Skin. In: Edge SB, Byrd DR, Compton CC Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:325-344.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
3. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.
4. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818-1825.
5. Suciu S, Ives N, Eggermont AM, et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7500 melanoma patients [abstract 9064]. J Clin Oncol. 2014;32(suppl):5s.
6. National Comprehensive Cancer Network Guidelines Melanoma V 22014. Available at: www.nccn.org.
7. Clinical Trials Registry 2014. Available at: http://www. clinicaltrials.gov.
8. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol. 2014;32. Abstrc No: LBA9008.
9. Lawson DH, Lee SJ, Tarhini AA, et al. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol. 2010;28, (suppl; abstr 8504).
10. Leukine (Sanofi), A Recombinant GM CSF - Yeast Expressed, Prescribing Information 2013. Available at: http://www. clinicaltrials.gov.
11. Chachoua A, Oratz R, Hoogmoed R, et al. Monocyte activation following systemic administration of granulocyte- macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol. 1994;15:217-224.
12. Demir G, Klein HO, Tuzuner N. Low dose daily rhGM-CSF application activates monocytes and dendritic cells in vivo. Leuk Res. 2003;27:1105-1108.
13. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metal-loelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997;88:801-810.
14. Young JW, Szabolcs P, Moore MA. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med. 1995;182:1111-1119, [published erratum appears in J Exp Med. 1996 Mar 1;183(3):1283].
15. Szabolcs P, Moore MA, Young JW. Expansion of immunostimu-latory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol. 1995;154:5851-5861.
16. Szabolcs P, Avigan D, Gezelter S, et al. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood. 1996;87:4520-4530.
17. Daud AI, Mirza N, Lenox B, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008;26:3235-3241.
18. Grotz TE, Kottschade L, Pavey ES, et al. Adjuvant GM-CSF Improves Survival in High-risk Stage IIIC Melanoma: A Single-center Study. Am J Clin Oncol. 2013;31. [Epub ahead of print].
19. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macro-phage colony-stimulating factor [see comments]. J Clin Oncol. 2000;18:1614-1621.
20. Spitler LE, Weber RW, Allen RE, et al. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sar-gramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother. 2009;32:632-637.
21. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. ASCO, J Clin Oncol. 2013;31(suppl). Abstr CRA9007.
22. Cantrell MA, Anderson D, Cerretti DP, et al. Cloning, sequence, and expression of a human granulocyte/macrophage colony-stimulating factor. Proc Natl Acad Sci USA. 1985;82: 6250-6254.
23. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther. 1993;15:19-29.
24. Huber C, Batchelor JR, Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984;160:310-316.
25. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev. 1991;15:483-490.
26. Crispino S, Lissoni P, Ardizzoia A, et al. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients. J Biol Regul Homeost Agents. 1993;7:92-94.
27. Marth C, Weiss G, Koza A, et al. Increased production of immune activation marker neopterin by colony-stimulating factors in gynecological cancer patients. Int J Cancer. 1994;58:20-23.
28. Gribben JG, Devereux S, Thomas NS, et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. 1990;335:434-437.
29. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood. 1994; 84:4078-4087.
30. Sredni B, Caspi RR, Klein A, et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature. 1987;330:173-176.
31. Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodys-plastic syndrome: toxicity, pharmacokinetics, and hematological effects. J Clin Oncol. 1989;7:629-637.
32. Ullenhag G, Bird C, Ragnhammar P, et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunosti-mulation. Clin Immunol. 2001;99:65-74.
33. Wadhwa M, Bird C, Fagerberg J, et al. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin Exp Immunol. 1996;104:351-358.
34. Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res. 1999;5:1353-1361.
35. Rini B, Wadhwa M, Bird C, et al. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine. 2005;29:56-66.
36. Terai M, Sakashita H, Mastrangelo MJ, et al. Development of antibodies to granulocyte-macrophage colony stimulating factor (GM-CSF) after embolization of the hepatic artery with GM-CSF. Proceedings of AACR; 2005; Anaheim, CA; 5994a.
37. McNeel DG, Schiffman K, Disis ML. Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1999;93:2653-2659.